FDA PCAC Meeting July 2026: 7 Peptides Under Review

The Official Announcement

The FDA published the formal meeting notice in the Federal Register on April 16, 2026 as Docket FDA-2025-N-6895. The two-day public meeting will be held at the FDA White Oak Campus (Bldg. 31, Room 1503), Silver Spring, MD, with online teleconference access. Day 1 runs 8:00 AM to 4:30 PM Eastern; Day 2 runs 8:00 AM to 3:50 PM Eastern. The full notice is available at federalregister.gov/d/2026-07361.

This is the meeting the April 15 reclassification action was pointing toward. The Federal Register notice confirms the seven peptides on the July agenda and the specific conditions the FDA has reviewed for each. It does not, at this stage, disclose the agency's position. That will appear in the PCAC briefing documents, which the FDA says will be made public "no later than 2 business days before the meeting."

What the PCAC Actually Does

The Pharmacy Compounding Advisory Committee is a federal advisory committee of external experts that advises the FDA on compounding policy. Its central task is evaluating nominated substances for the 503A Bulks List — the roster of bulk drug substances that 503A pharmacies can legally compound when no USP monograph exists and the substance isn't a component of an already-approved drug.

At the meeting, the FDA presents its review of each substance. Nominators and the public can present. The committee then votes on a recommendation. The vote is advisory, not binding — the FDA retains final rulemaking authority — but historically the agency has given substantial weight to PCAC recommendations when drafting final rules. A favorable PCAC vote does not put a substance on the 503A Bulks List. It only initiates the formal rulemaking pipeline that could add it.

In plain terms: July 23-24 is where the scientific and safety case gets argued. It is not where the legal status changes. Compounding of these peptides remains outside FDA enforcement discretion both during and after the meeting, until the agency publishes a final rule through the normal rulemaking process.

Day 1 (July 23): BPC-157, KPV, TB-500, MOTs-C

The Committee will review four peptides on Day 1. The FDA docket identifies the specific clinical uses under evaluation for each.

BPC-157 (Body Protection Compound) is the most-discussed compound on the agenda and has the narrowest indication under review. The FDA is evaluating it specifically for ulcerative colitis — not the broader tendon, ligament, and gut-healing uses that dominate non-clinical discussion. Much of the preclinical literature on BPC-157 is in animal models of colitis, so the UC indication aligns with the strongest existing evidence base. See our BPC-157 page for the underlying science.

KPV, a tripeptide derived from alpha-MSH, is under review for wound healing and inflammatory conditions — both systemic and topical. It has emerging evidence in inflammatory bowel disease and dermatologic applications. See our KPV page.

TB-500 (a synthetic fragment of thymosin beta-4) is being reviewed for wound healing. The indication is narrower than the general "systemic healing" framing often seen online, but it tracks the compound's most-studied mechanism: actin regulation and angiogenic tissue repair. See our TB-500 page.

MOTs-C, a mitochondrial-derived peptide, is under evaluation for obesity and osteoporosis. Unlike the other three, MOTs-C has more limited clinical literature and its inclusion on the agenda will be a notable indicator of how the committee weighs preclinical mechanism-of-action data against human outcome data.

Day 2 (July 24): Emideltide, Semax, Epitalon

The second day covers three additional peptides. None of the three are as broadly discussed in consumer peptide media as the Day 1 compounds, but each has specific clinical applications the FDA is formally reviewing.

Emideltide is the FDA's preferred name for delta sleep-inducing peptide (DSIP). The indications under review — opioid withdrawal, chronic insomnia, and narcolepsy — reflect the compound's historical Russian and Eastern European clinical literature, which is substantially older than most of the English-language peptide research. See our DSIP page.

Semax is a synthetic heptapeptide originally developed in Russia and approved there for cerebrovascular and cognitive indications. The FDA review covers cerebral ischemia, migraine, and trigeminal neuralgia — neurological applications where the Russian clinical literature is most extensive. See our Semax page.

Epitalon, a tetrapeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology, is under review only for insomnia. The broader anti-aging and telomere claims commonly attached to Epitalon in consumer peptide media are not part of the FDA's review scope. See our Epithalon page.

How Public Comment Works

The public comment window is open. The FDA has established Docket FDA-2025-N-6895 on regulations.gov. Anyone — clinician, pharmacist, patient, researcher, industry stakeholder, or member of the public — can submit a comment.

Key dates from the Federal Register notice:

• June 30, 2026 — Deadline to request time for formal oral presentation at the meeting (including brief statement of what you plan to present, names of participants, in-person or online preference)
• July 1, 2026 — FDA notifies requesters of their speaking slot
• July 9, 2026 — Deadline for comments that will be provided directly to the Committee before the meeting
• July 22, 2026 — Final docket close (11:59 PM Eastern); comments received after this date will not be considered in the meeting record
• July 23-24, 2026 — The PCAC meeting itself

Comments can be submitted electronically at regulations.gov (search Docket FDA-2025-N-6895), or by mail to Dockets Management Staff (HFA-305), FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Electronic submissions are posted publicly unchanged, so commenters should not include personally identifying information in the body of a comment if they want it private.

What to Watch For in the Briefing Documents

The FDA's briefing documents are released roughly two business days before the meeting — so around July 21 for Day 1 and July 22 for Day 2. Based on past PCAC materials, these documents typically include:

The FDA's safety review. This is the most important section. It covers current good manufacturing practice (CGMP) concerns, impurity profiles from available material, immunogenicity signals, adverse event reports filed with the FDA, and any documented cases from animal or human exposure.

The nominator dossier. Each substance was nominated by an outside party — typically a compounding pharmacy, trade association, or patient advocacy group. Their dossier lays out the clinical rationale, evidence base, and proposed labeling framework.

The FDA's own literature review. A systematic look at published clinical and preclinical evidence for the specific indications under review. This section often surfaces evidence-base gaps that consumer-facing discussion glosses over.

Any pharmacovigilance data. If the FDA has received adverse event reports for any of these peptides — even through off-label or grey-market use — those reports are often summarized.

For anyone tracking the scientific merits of the peptides on review, the briefing documents are substantially more informative than the meeting itself. The meeting is where the arguments get made. The briefing document is where the underlying evidence base gets laid out.

What the Meeting Can and Cannot Do

Several things are worth being clear about, given how this kind of regulatory news tends to get compressed in consumer coverage:

The meeting does not change legal status. Whether the PCAC votes favorably or unfavorably on a substance, the July 23-24 meeting does not legalize compounding of any peptide. Substance addition to the 503A Bulks List requires formal FDA rulemaking that occurs after — and substantially later than — the PCAC vote.

A favorable vote is not approval. PCAC recommendations are advisory. The FDA can accept, modify, or decline to act on them. Historically, the agency aligns with clear PCAC consensus, but the process from vote to final rule can take months to years.

An unfavorable vote is not final rejection. The FDA has declined to act on favorable PCAC votes before, and has later revisited substances that initially received unfavorable recommendations when new evidence emerged. A "no" vote signals a substantial delay, not a permanent one.

The review scope is specific. Each peptide is being evaluated for the specific clinical use(s) listed in the Federal Register notice. A vote in favor of BPC-157 for ulcerative colitis is not a vote in favor of BPC-157 for general tendon healing or performance enhancement. Labeling and indication language matters to the outcome.

Why This Meeting Matters

The July PCAC meeting is the first substantive public review of the safety and clinical evidence for these seven peptides in the 503A framework. The conditions being evaluated are specific and narrow — much narrower than most consumer-facing discussion of these compounds. The FDA's review will, for the first time, make public what the agency actually thinks about each compound's risk-benefit profile for the indications under consideration.

For clinicians, pharmacists, and researchers, the briefing documents and the committee discussion will likely surface information not currently in the published literature. For patients who have used or are considering these compounds, the meeting provides the clearest public articulation to date of what the federal regulatory framework will actually permit.

The regulatory story around these peptides has been moving for years — mostly in fits and starts, often slower than consumer coverage has implied. The July meeting is a real, documented milestone. It is not the final word.